abstract |
Use of the proprietary drug amiloride for the treatment of cancer types that depend on an enzymatic cascade triggered by the activation of plasminogen to plasmin by the specific activating enzyme Urokinase Plasminogen Activator (uPA). Administration of amiloride inhibits the action of uPA, inhibits the ability of the cancer cell to attract new blood supply, blocks the Na+/H+ transporter, and inhibits ornithine decarboxylase necessary for DNA synthesis. Further, in combination with amiloride, a different step in the enzymatic cascade is targeted by a secondary agent, Batimistat, for example, which is a metalloprotease inhibitor. Additionally, the use of hydrochlorothiazide promotes excretion of potassium. |